Service & Supply

Here are your up-to-date news results!
Clicking the title of the article will give you the original publication.
You can share an article quickly with colleagues via Twitter and LinkedIn!


Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
Published:

Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease. “Our annotation library of over 1.4M small RNA

The post Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery appeared first on Pharmaceutical Business review.

AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
Published:

This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and

The post AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations appeared first on Pharmaceutical Business review.

Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Published:

GvHD is a potentially life-threatening medical complication, which can affect patients receiving such transplants to treat certain genetic diseases and haematologic cancers. Orencia is an immunomodulator that disturbs

The post Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD appeared first on Pharmaceutical Business review.

AstraZeneca sells US, Canada rights of Seroquel drugs to Cheplapharm
Published:

The transaction has been taken up by AstraZeneca as the compound patent protection of the two drugs is no longer valid in the two countries. It would also

The post AstraZeneca sells US, Canada rights of Seroquel drugs to Cheplapharm appeared first on Pharmaceutical Business review.

Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Published:

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review

The post Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS appeared first on Pharmaceutical Business review.

IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
Published:

The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties. IONTAS’

The post IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets appeared first on Pharmaceutical Business review.

Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC
Published:

The approval has been granted for Tecentriq in combination with Abraxane (paclitaxel protein-bound; nab-paclitaxel) and carboplatin for the first-line treatment of adults with metastatic NSCLC with no EGFR

The post Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC appeared first on Pharmaceutical Business review.

STADA to acquire Biopharma’s prescription and consumer health business
Published:

As part of the deal, STADA will also acquire Biopharma’s two GMP-certified production facilities in the city of Bila Tserkva, Kiev. The shareholders of Biopharma will retain the

The post STADA to acquire Biopharma’s prescription and consumer health business appeared first on Pharmaceutical Business review.

Knopp Biosciences, University of Leicester release details of phase 2 trial of dexpramipexole in severe eosinophilic asthma
Published:

The 52-week, randomized, double-blind, placebo-controlled trial will evaluate whether dexpramipexole is associated with a reduction in asthma exacerbations. Fifteen severe asthma centers across the United Kingdom (UK) will

The post Knopp Biosciences, University of Leicester release details of phase 2 trial of dexpramipexole in severe eosinophilic asthma appeared first on Pharmaceutical Business review.

Rare disease diagnostics firm Centogene completes $52mm IPO on Nasdaq
Published: 26 Nov 2019 | 5:40 UTC

German biotech Centogene BV (rare disease diagnostics and biomarker discovery) netted $52mm in its initial public offering on Nasdaq of 4mm shares at $14, the low end of its anticipated $14-16 range.

Exagen completes $53.9mm IPO, five years after first filing
Published: 19 Nov 2019 | 17:29 UTC

Exagen Diagnostics Inc. (autoimmune disease testing and therapeutic drug monitoring) netted $53.9mm through its initial public offering of 4.14mm common shares (including the overallotment) at $14. The company first filed for an IPO back in 2014, but never completed the process.

Sera Prognostics closes $36mm Series D round
Published: 15 Nov 2019 | 5:40 UTC

Sera Prognostics Inc. (proteomics tests for the early prediction of preterm birth defects and other pregnancy-related complications) closed a $36mm Series D round co-led by new investor Blue Ox Healthcare and two undisclosed healthcare companies. Returning backers Domain Associates, InterWest Partners, Laboratory Corp. of America Holdings, Catalyst Health Ventures, and Chione Ltd. also participated. The company will use the proceeds to expand commercialization of and improve its clinically validated PreTRM, a biomarker blood test that assesses individualized risk of premature delivery. Since its 2008 inception, Sera has raised $122mm.

Quotient nets $79mm via FOPO
Published: 9 Nov 2019 | 5:40 UTC

Quotient Ltd. netted $79mm in a follow-on public offering of 12mm ordinary shares prices at $7 each. The company will use some of the funds for ongoing development and commercialization of its MosaiQ blood grouping and serological donor disease screening platform.

Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat
Published: 8 Nov 2019 | 5:40 UTC

Epizyme Inc. assigned Royalty Pharma the future royalty streams on Japanese sales of tazemetostat (an oral EZH2 inhibitor candidate for both solid tumors and hematological malignancies). In exchange, Epizyme could receive as much as $570mm in financing, with up to a $200mm equity investment from Royalty Pharma and up to $370mm in debt financing from Pharmakon Advisors, a Royalty Pharma affiliate. Epizyme has appointed a representative from Royalty Pharma to its board.

Y-mAbs nets $135mm through public stock sale
Published: 1 Nov 2019 | 3:40 UTC

Y-mAbs Therapeutics Inc. netted $135mm through a public offering of 5.1mm common shares (including the overallotment) at $28. Proceeds will support ongoing development of the company's oncology pipeline including pivotal-stage candidates naxitamab (for pediatric patients with relapsed or refractory high-risk neuroblastoma) and radiolabeled omburtamab (pediatric patients with central nervous system leptomeningeal metastases from neuroblastoma).

Public offering nets $188mm for Natera
Published: 23 Oct 2019 | 3:40 UTC

Natera Inc. netted $188mm through a public offering of 5.7mm common shares at $35. The company is developing molecular diagnostics for reproductive health, oncology (treatment and recurrence monitoring and molecular residual disease testing), and transplant rejection assessment.

Opko, BMS aim to develop Alzheimer’s blood test
Published: 23 Oct 2019 | 3:40 UTC

Opko Health Inc. (point-of-care and molecular diagnostics and vaccines) and Bristol-Myers Squibb Co. will nonexclusively collaborate on the further development of Opko’s Alzheimer’s disease blood test.

BioNTech nets $148.3mm through initial public offering
Published: 22 Oct 2019 | 21:18 UTC

BioNTech SE (immuno-oncology) netted $148.3mm through its initial public offering of 10.5mm American Depositary Shares (representing 10.5mm ordinary; includes partial exercise of the overallotment) at $15. The company had planned to sell 13.2mm ADSs at a range of $18-20.



Please note that GR Consulting can not alter or influence the messages displayed, nor is it responsible for its content. If needed or desired, please refer to the original message and/or its originator.